VistaGen Therapeutics, Inc. Average Receivables

Average Receivables of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Average Receivables growth rates and interactive chart.


Highlights and Quick Summary

  • Average Receivables for the quarter ending March 30, 2019 was $154 Thousand (a -27.93% decrease compared to previous quarter)
  • Year-over-year quarterly Average Receivables increased by 107.41%
  • Annual Average Receivables for 2019 was $203 Thousand (a 173.72% increase from previous year)
Visit stockrow.com/VTGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Average Receivables of VistaGen Therapeutics, Inc.

Most recent Average Receivablesof VTGN including historical data for past 10 years.

Interactive Chart of Average Receivables of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. Average Receivables for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $0.15 $0.2
2018 $0.21
2016 $0.7
2012 $0.07 $0.07

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.